has Server used IP Address with Hostname in France. Below listing website ranking, Similar Webs, Backlinks. This domain was first Unknown and hosted in France, server ping response time 150 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Hivfrenchresistance keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

Notice! No data available for this site.

Hosting Provider

Latitude: 48.858200073242
Longitude: 2.338700056076
Area Code: 0
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain

New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » (1 day ago)

   » (1 day ago)

   » (20 hours ago)

   » (4 hours ago)

   » (11 day ago)

   » (5 day ago)

   » (21 hours ago)

Results For Websites Listing

Found 48 Websites with content related to this domain, It is result after search with search engine

HIV French Resistance   DA: 27 PA: 27 MOZ Rank: 54

  • The accumulation of retrospective and prospective data has led expert panels to recommend the use of resistance testing in the decision of treatment of HIV-infected patients
  • The French ANRS (National Agency for AIDS Research) AC43 Resistance group provides HIV-1 genotypic drug resistance interpretation’s algorithms in order to guide

HIV Resistance Assays   DA: 21 PA: 46 MOZ Rank: 68

  • HIV French Resistance Database; HIV InSite Links: HIV Resistance and Resistance Testing; Two methods are used to determine drug resistance for HIV: genotyping, which detects treatment-resistant genetic mutations; and phenotyping, which assesses the viral response to ART agents
  • Genotyping is the preferred test in most clinical situations.

Antiretroviral Drug Resistance And Routine Therapy   DA: 13 PA: 33 MOZ Rank: 48

HIV drug resistance is a major threat to the scaling up of antiretroviral therapy (ART) in developing countries (the World Health Organization/United Nations Programme on HIV/AIDS "3 by 5" Initiative) (), especially in Africa ().Inadequate clinical and biological follow-up has been linked to high rates of drug resistance (>50% after 8 to 20 months) in Gabon (), Côte d'Ivoire (), and Uganda ().

HIV Drug Resistance Mutations   DA: 14 PA: 41 MOZ Rank: 58

  • HIV French Resistance, French ANRS (National Agency for AIDS Research) AC11 Resistance Group; Journal Articles
  • The IAS–USA has many resources related to HIV drug-resistant mutations
  • Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection – Recommendations from IAS–USA panels

Tipranavir-Ritonavir Genotypic Resistance Score In   DA: 20 PA: 25 MOZ Rank: 49

  • The end point for the analysis was the percentage of responders at month 3
  • VR was defined by a decrease of at least 1 log 10 in HIV RNA from baseline or HIV RNA less than the LOQ at month 3
  • These criteria were also used in the RESIST (Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients with Tipranavir) studies and the FDA TPV resistance

Determination Of Reverse Transcriptase Inhibitor   DA: 23 PA: 10 MOZ Rank: 38

  • Treatment scale-up is leading to a progressive increase in HIV resistance to antiretrovirals, especially in children
  • To assess resistance to reverse transcriptase inhibitors (RTIs) in HIV-1 infected children in Côte d'Ivoire, genotypic resistance tests were performed and interpreted using the ANRS algorithm (

French National Survey Of Resistance To Integrase   DA: 30 PA: 30 MOZ Rank: 66

Objectives of the study • Primary objective: • To characterize resistance patterns in case of virological failure to integrase inhibitor-based regimen in clinical setting from the french

Transmission Of HIV-1 Minority-resistant Variants And   DA: 16 PA: 50 MOZ Rank: 73

Resistance mutations were reported as listed by the International AIDS Society, USA Panel (, update October 2005), including revertant mutations at reverse transcriptase codon 215, and/or the ANRS algorithm version 2006 (, excluding minor protease mutations and the V118I reverse transcriptase mutation.

Integrase Inhibitors-Transmitted Drug Resistance Detected   DA: 22 PA: 50 MOZ Rank: 80

  • Resistance was interpreted according to the last version of ANRS algorithm (
  • Among the 65 patients, 60% of them were infected by B subtype
  • Viruses of six patients harbored majority resistant mutations by Sanger sequencing (four L74I and two E157Q mutations).

Resistance To Nucleoside Reverse Transcriptase Inhibitors   DA: 20 PA: 15 MOZ Rank: 44

  • Resistance and cross-resistance to nucleoside reverse transcriptase inhibitors (NRTIs) is becoming better understood
  • This is a complex phenomenon, which involves mutations that occur under the selective pressure of drugs and interactions between mutations
  • Resistance studies have highlighted distinct evolution patterns of mutations and cross-resistance among the NRTIs, which have the ability

Anne-Geneviève Marcelin, MD AME   DA: 28 PA: 27 MOZ Rank: 65

She serves as a member of Agence Nationale de Recherches sur le SIDA et les hepatites virales (ANRS), in the French AC43 resistance group ( and is chair of the ANRS Next generation sequencing network.

CAB + RPV Failure Risk Factor In 10% Of Large French Cohort   DA: 13 PA: 20 MOZ Rank: 44

  • The investigators analyzed these viral sequences for RPV and CAB resistance-associated mutations by combining the French ANRS algorithm ( and the IAS-USA list [3]
  • The Paris team evaluated 4212 HIV-1 sequences from 4212 antiretroviral-naive people with both reverse transcriptase and integrase sequences available.

Routine Drug Resistance Testing In HIV-1 Proviral DNA   DA: 21 PA: 38 MOZ Rank: 71

  • HIV-1 DNA genotypic drug resistance testing can be useful in controlled patients
  • • The Sentosa NGS platform allowed fully automated resistance testing in HIV-1 RNA samples.

Genotypic Testing For HIV-1 Drug Resistance   DA: 18 PA: 7 MOZ Rank: 38

Rationale for HIV-1 Drug Resistance Testing: Nineteen antiretroviral drugs have been approved for the treatment of HIV-1 infection: one nucleotide and seven nucleoside reverse transcriptase inhibitors (NRTIs), seven protease inhibitors (PIs), three nonnucleoside RT inhibitors (NNRTIs), and one fusion inhibitor.

Multiple HIV-1/M + HIV-1/O Dual Infections And New HIV-1   DA: 31 PA: 35 MOZ Rank: 80

  • Due to the prevalence of HIV-1 group M and the endemicity of HIV-1 group O infections in Cameroon, patients may be infected with both viruses and/or with HIV-1/MO recombinant forms
  • Such atypical infections may be deleterious in terms of diagnosis and therapeutic management due to the high divergence of HIV-1/O
  • The aim of this study was to identify prospectively such atypical infections in

Sexual Transmission Of An Extensively Drug-resistant HIV-1   DA: 17 PA: 50 MOZ Rank: 82

  • Emergence of drug-resistant HIV-1 has long been identified as a public health threat.1 However, there has so far been little transmission of multidrug-resistant strains, probably because of reduced replication fitness of highly mutated strains that makes them less adapted for establishing infection than wild-type strains among the viral quasispecies
  • In HIV-1 primary infections in France, less

Short Communication: Prevalence Of HIV-1 Transmitted Drug   DA: 23 PA: 10 MOZ Rank: 49

  • Protease and reverse transcriptase (RT) regions sequencing was performed using the ANRS procedures (
  • Drug resistance mutations (DRM) were identified according to the 2009 updated WHO surveillance DRM list
  • Among the 116 HIV-1-infected patients enrolled in …

HIV-1 Pol Gene Polymorphism And Antiretroviral Resistance   DA: 16 PA: 50 MOZ Rank: 83

  • To the Editor: A recent demographic and health survey was performed in Cameroon in 2004 that showed an HIV-1 seroprevalence rate of 5.5% in the general population
  • 1 In Yaoundé, the capital city of Cameroon, HIV-1 prevalence is as high as 10% among pregnant women attending antenatal centers
  • 2 Since the year 2000, a public health pilot program for the prevention of mother-to-child

Comparison Of Susceptibility Of HIV-1 Variants To   DA: 21 PA: 38 MOZ Rank: 77

  • This study utilized genotypic and in-house recombinant virus phenotypic assays to examine HIV-1 variant susceptibility to antiretroviral (ARV) drugs; …

Utility Of POC Xpert HIV-1 Tests For Detection   DA: 14 PA: 28 MOZ Rank: 61

  • Point-of-Care (POC) molecular assays improve HIV infant diagnosis and viral load (VL) quantification in resource-limited settings
  • We evaluated POC performance in …

HIV-1 Acquired Drug Resistance To Integrase Inhibitors In   DA: 32 PA: 35 MOZ Rank: 87

  • Background In resource-limited settings, multi-experienced HIV infected patients are often prescribed raltegravir for salvage therapy
  • Patients failing raltegravir-containing regimens require other drugs including other integrase inhibitors
  • In this context, real-life data about the resistance and cross-resistance pathways between integrase inhibitors is limited

Molecular Evolution Of HIV-1 Integrase During The 20 Years   DA: 27 PA: 35 MOZ Rank: 83

  • Detailed knowledge of the evolutionary potential of polymorphic sites in a viral protein is important for understanding the development of drug resistance in the presence of an inhibitor
  • We therefore set out to analyse the molecular evolution of the HIV-1 subtype B integrase at the inter-patient level in Germany during a 20-year period prior to the first introduction of integrase strand

Moderate Prevalence Of HIV-1 Transmitted Drug Resistance   DA: 32 PA: 35 MOZ Rank: 89

  • Despite the advances in therapy, the occurrence of drug-resistant human immunodeficiency virus type 1 (HIV-1) is a major obstacle to successful treatment
  • This study aimed to characterize the genetic diversity and to determine the prevalence of transmitted drug resistance mutations (TDRM) between individuals recently or chronically diagnosed with HIV-1 from Paraná, Brazil.

Genetic Diversity And Antiretroviral Drug Resistance Among   DA: 25 PA: 50 MOZ Rank: 98

  • Scientific Research (ANRS - and that of the Max Plank ( for identification of the subtypes of HIV-1 and possible mutations
  • Minor adjustments of the bases were performed if necessary to align the sequences
  • Statistics The Friedman test was used to analyze differences in the groups variants

Protease Inhibitor Resistance Mutation Profile In Children   DA: 17 PA: 33 MOZ Rank: 74

  • Protease inhibitors (PIs) select more mutations than any other class of antiretroviral drugs (ARV)
  • The objective of our study was to determine minor and major mutations in HIV-1 protease that may decrease the efficacy of PIs in children
  • The determination of mutations and their interpretations were performed using ANRS techniques and algorithms (

Antiretroviral Drug Resistance Among Drug-Naive HIV-1   DA: 20 PA: 31 MOZ Rank: 76

  • Genotypic studies were performed with viral RNA from plasma using the consensus technique of the Agence Nationale de Recherche sur le SIDA (
  • Mutations were identified using the International AIDS Society-USA resistance panel …

Antiretroviral Resistance In HIV-Infected Persons At   DA: 18 PA: 50 MOZ Rank: 94

  • The genotypic resistance testing (GRT) were performed and interpreted according to the ANRS algorithm (
  • Phylogenetic trees were created using BioEdit v7 and Mega7 software
  • Phylogenetic analysis showed that CRF02_AG (83%) was the most represented.

Risk Factors For Virological Failure And Subtherapeutic   DA: 30 PA: 32 MOZ Rank: 89

  • Little is known about immunovirological treatment outcomes and adherence in HIV/AIDS patients on antiretroviral therapy (ART) treated using a simplified management approach in rural areas of developing countries, or about the main factors influencing those outcomes in clinical practice
  • Cross-sectional immunovirological, pharmacological, and adherence outcomes were evaluated in all patients

Prevalence Of Pretreatment HIV Drug Resistance In Key   DA: 23 PA: 23 MOZ Rank: 74

  • We extracted the following variables: year of publication, years of data collection, the country in which the study was performed, prior exposure to antiretroviral therapy, total sample size, number belonging to each key population, number of people enrolled, number of people with successfully tested genotypes, and number of genotypes with resistance mutations (any PDR

Virological Response, HIV-1 Drug Resistance Mutations And   DA: 29 PA: 35 MOZ Rank: 93

  • The national antiretroviral therapy in the Republic of Chad provides free of charge antiretroviral regimens and therapeutic monitoring for patients receiving antiretroviral therapy nationwide
  • For a successful programmatic uptake, these efforts merit to be supported by thorough assessments of antiretroviral therapy response and HIV-1 drug resistance surveillance, especially with risks of cross

Prevalence Of Pre-existing Resistance-associated Mutations   DA: 16 PA: 29 MOZ Rank: 75

  • These substitutions are included in the US FDA list of rilpivirine-associated substitutions as noted in the US package insert
  • 12, 21 Other potential rilpivirine-associated mutations are V90I, L100I, K101T, E138S, V179D/I, Y188L, V189I, G190A/E/S and M230V as cited in in vitro or/and in vivo studies 14, 22 and/or the Agence Nationale de

Eddy Palacci   DA: 16 PA: 18 MOZ Rank: 65

  • Colette Rossant (sister), Juliette Rossant (niece) Family
  • Edmond Vita Palacci (1931–2016), generally known as " Eddy Palacci ," was a French - Israeli chemical engineer and author, whose memoirs recount his survival in Occupied France during World War II and help for the French Resistance.

Anthropometric And Immunological Success Of Antiretroviral   DA: 11 PA: 36 MOZ Rank: 79

  • 436 Bulletin of the World Health Organization | June 2008, 86 (6) Research Virological success of antiretroviral therapy Eugène Messou et al
  • Methods Patients In December 2002, a …

Resistance Associated Mutations To Etravirine (TMC-125) In   DA: 9 PA: 23 MOZ Rank: 65

Resistance Associated Mutations to Etravirine (TMC-125) in Antiretroviral Naïve Patients infected with non-B HIV-1 subtypes Download the PDF here

Genetic Diversity And Antiretroviral Drug Resistance Among   DA: 25 PA: 32 MOZ Rank: 91

The pairing of the resulting fragments (sense and antisense) was performed with the software Vector NTI Advance® 11.5 (Invitrogen, Life Technologies) and compared with the Stanford University database ( [16], that of the French National Agency for Scientific Research (ANRS - and that of the Max

RESEARCH Open Access HIV-1 Drug Resistance Genotyping …   DA: 37 PA: 38 MOZ Rank: 15

RESEARCH Open Access HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients

The Evolution Of Drug Resistance Interpretation Algorithms   DA: 23 PA: 30 MOZ Rank: 89

  • EberGerl/el üt r 130 Intervirology 2012;55:128–133 The study of van de Vijver et al
  • [12] showed a diver-gence of 25–70% in the results (i.e
  • resistant and possibly resistant) of a virtual phenotypic assay and a genotypic

Journal Of Tchiakpe Et Al, Antivir Antiretrovir 214, :3   DA: 15 PA: 50 MOZ Rank: 13

  • resistance study group protocol (http: //www.hivfrenchresistance
  • The same protocol of the ANRS AC11 was also used to amplify the first 288 amino acids for integrase gene with the primers previously described by Monleau [9]
  • The PCR products were purified and sequenced on the …

Efficacy Of Etravirine Combined With Darunavir Or Other   DA: 13 PA: 21 MOZ Rank: 72

  • Objectives This observational study in antiretroviral treatment-experienced, HIV-1-infected adults explored the efficacy of etravirine plus darunavir/ritonavir (DRV group; n = 999) vs
  • etravirine plus an alternative boosted protease inhibitor (other PI group; n = 116) using pooled European cohort data.

Baseline CD4+ T-cell Counts And Weighted Background   DA: 20 PA: 25 MOZ Rank: 84

  • BackgroundMaraviroc-containing regimens are known to achieve virological suppression in many treatment-experienced patients
  • This study aimed to evaluate a …

The Global Burden Of HIV-1 Drug Resistance In The Past 20   DA: 9 PA: 18 MOZ Rank: 67

  • v.26 (France) (HIV French Resistance,2017), Rega v.9.1 (Belgium) (Ku Leuven,2017), and HIVdb v.8.4 (USA) (Stanford University, 2017)
  • Resistance to one single drug was defined as an intermediate/resistant scoring as per the Stanford’s standardized scale, including non-ritonavir boosted PI scoring
  • Resistance to a drug class (NRTI/NNRTI/PI) was

(PDF) Unravelling The Dynamics Of Selection Of   DA: 16 PA: 50 MOZ Rank: 9

Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing

NYSDOH AI Guideline HIV Resistance Assays   DA: 21 PA: 50 MOZ Rank: 8

  • to interpret the results of resistance assays because such results are often complex
  • (A3) - The NYSDOH AIDS Institute’s Clinical Education Initiative line is available for phone consultation: 866-637-2342.

Early Assessment Of Antiretroviral Efficacy Is   DA: 17 PA: 15 MOZ Rank: 75

  • Resistance mutations to NRTI and NNRTI were determined in all patients with plasma HIV-1 RNA >400 copies/ml at week 48 by sequencing the reverse transcriptase gene using the consensus technique of the AC11 ANRS Resistance Group ( at the Department of Virology, Necker Hospital (Paris, France)

Recently Analyzed Sites (1 day ago) (1 day ago) (20 hours ago) (4 hours ago) (11 day ago) (1 day ago) (2 day ago) (5 seconds ago) (16 hours ago) (2 day ago) (19 hours ago) (4 day ago)